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Osteoporosis is a disease of low bone mass most often caused by an increase in bone resorption that is not sufficiently compensated for by a corresponding increase in bone formation 1 . As gut-derived serotonin (GDS) inhibits bone formation 2 , we asked whether hampering its biosynthesis could treat osteoporosis through an anabolic mechanism (that is, by increasing bone formation). We synthesized and used LP533401, a small molecule inhibitor of tryptophan hydroxylase-1 (Tph-1), the initial enzyme in GDS biosynthesis. Oral administration of this small molecule once daily for up to six weeks acts prophylactically or therapeutically, in a dose-dependent manner, to treat osteoporosis in ovariectomized rodents because of an isolated increase in bone formation. These results provide a proof of principle that inhibiting GDS biosynthesis could become a new anabolic treatment for osteoporosis.
GDS is a powerful inhibitor of osteoblast proliferation and bone formation while not affecting bone resorption 2 . Thus, inhibiting GDS biosynthesis could be a means to treat low-bone-mass conditions through a bone anabolic mode of action. LP533401 is a small-molecule inhibitor of Tph-1, the initial enzyme in the GDS biosynthesis, currently being tested at a dose of 100 mg per kg body weight for treatment of irritable bowel syndrome with no overt deleterious side effects 3 . In vivo pharmacokinetic studies in rodents showed that the amount of LP533401 in the brain is negligible after oral administration, indicating that it is virtually incapable of crossing the blood-brain barrier 3, 4 . This latter point is crucial, as brain-and gut-derived serotonin exert opposite influences on bone formation 5 . Thus, LP533401 seems to be a good tool to test the therapeutic potential of specifically inhibiting GDS biosynthesis for low-bonemass diseases.
We used the available chemical procedure 4 to synthesize LP533401 and verified its structural identity by multiple analyses (Supplementary Fig. 1 ). To evaluate LP533401 efficacy in inhibiting serotonin biosynthesis, we treated Tph1-expressing cells (rat RBL2H3 cells) for 3 d with increasing amounts of LP533401 (0.1-1 µM). LP533401 completely inhibited serotonin production in these cells at a dose of 1 µM (Fig. 1a) . Moreover, there was a dose-dependent decrease in serum serotonin concentration in WT mice fed with LP533401 ( Fig. 1b) . This decrease in serum serotonin concentration reached 30% of control values at 250 mg per kg body weight per day of the compound, although we did not observe any change in brain serotonin content ( Supplementary Fig. 2) .
To elucidate how LP533401 influences TPH-1 activity, we performed in silico and ex vivo analyses. We used the crystal structure of the TPH-1 enzymatic domain with its cofactor 7,8-dihydro-l-biopterin (HBI) 6 as a reference in studying interactions of LP533401 with TPH-1 catalytic regions ( Fig. 1c) . We generated a three-dimensional model for LP533401 from its chemical structure and docked it onto the three-dimensional structure of TPH-1 to identify interactions between these two molecules. We analyzed various conformers of LP533401 docked to TPH-1, and selected for further analysis the three-dimensional model showing the strongest interaction between LP533401 and TPH-1; that is, the model having the lowest estimated free energy for binding (−9.46 kcal mol −1 ) ( Fig. 1d ). This docked model of LP533401 with TPH-1 revealed that LP533401 interacts with two amino acids, Tyr235 and Phe241, near the TPH-1 catalytic site ( Fig. 1d) . To verify the importance of these residues in mediating the interaction of LP533401 with TPH-1, we generated recombinant wild-type TPH-1 or a mutated form in which Tyr235 and Phe241 were replaced by a serine and a valine, respectively. Whereas LP533401 decreased the activity of wild-type TPH-1 by more than 70%, the mutations markedly blunted this effect ( Fig. 1e) . These results indicate that, as predicted by the docked model, LP533401 inhibits TPH-1 activity, in part by interacting with residues Tyr235 and Phe241.
Next we tested the relevance of LP533401 as a treatment for lowbone-mass diseases, through the use of ovariectomized rodents. As seen clinically in postmenopausal women 1 , this disease model shows a higher increase in bone resorption than the increase in bone formation that is also caused by gonadal failure, thus leading to a net loss of bone 7 . We first asked whether LP533401 could prevent ovariectomyinduced bone loss if treatment was started immediately after ovariectomy. We fed 6-week-old sham-operated or ovariectomized female C57BL6/J mice once daily with either vehicle or LP533401 at doses ranging from 1 to 250 mg per kg body weight per day from day 1 to day 28 after ovariectomy ( Fig. 2a and Supplementary Fig. 3a) . Osteoclast surface and serum levels of deoxypyridinoline, a marker of bone resorption, were higher in ovariectomized mice, regardless of their treatment, than in sham-operated mice, and, as a result, vehicletreated ovariectomized mice developed a low bone mass (osteopenia) ( Fig. 2a and Supplementary Fig. 3b ). In contrast, mice treated with 250, 100 or even 10 mg per kg body weight per day of LP533401 had a higher bone mass than did vehicle-treated ovariectomized mice ( Fig. 2a) . Consistent with the influence of GDS on osteoblast proliferation and bone formation, this increase in bone mass in the LP533401-treated ovariectomized mice was secondary to a major increase in bone-formation parameters such as osteoblast numbers, bone formation rate, and osteocalcin serum concentration ( Fig. 2a and Supplementary Fig. 3c,d) . There was no difference in osteoclast surface between ovariectomized mice treated with vehicle or LP533401, indicating that this compound does not affect osteoclast proliferation ( Fig. 2a ). We verified that although serum serotonin concentration decreased in a dose-dependent manner, brain serotonin content remained unaffected in LP533401-treated ovariectomized mice (Fig. 2b) . These results establish that LP533401 can prevent the development of ovariectomy-induced osteoporosis in mice.
The favorable effect that we observed on bone-formation parameters with a relatively small reduction in circulating serotonin concentrations (~30%) echoes what is observed in a genetic model of decreased circulating serotonin concentrations, in which the increase in bone-formation parameters observed in heterozygous mutant mice is not statistically different from the one seen in homozygous mutant mice 2 . This suggests that there is a threshold for the reduction in serum serotonin concentration beyond which the skeletal response is marginally increased.
We next asked whether LP533401 could also rescue existing ovariectomy-induced osteopenia. In an initial experiment, we left sham-operated or ovariectomized 6-week-old mice without treatment for only 2 weeks and then treated them with vehicle or a daily dose of LP533401 (250 mg per kg body weight per day) for 4 weeks (Fig. 2c) . Vehicle-treated ovariectomized mice developed the expected osteopenia secondary to an increase in bone resorption parameters ( Fig. 2c and Supplementary Fig. 3e ). These parameters were also increased in LP533401-treated ovariectomized mice; however, in these mice the increase in bone formation parameters was of such amplitude that it normalized their bone mass ( Fig. 2c) . Serum serotonin concentrations were decreased by 80%, but brain serotonin content was unaffected in LP533401-treated mice ( Fig. 2c and Supplementary Fig. 3f) .
Given the success of this initial experiment, we then asked whether LP533401 could rescue osteopenia even if administered substantially later after ovariectomy and at lower doses. We left 6-week-old ovariectomized mice untreated for 6 weeks before treating them with vehicle or LP533401 at either 25, 100 or 250 mg per kg body weight per day for another 6 weeks ( Fig. 2d) . LP533401, by increasing bone formation parameters, reversed the deleterious effects of ovariectomy on bone mass and increased it to levels similar to (25 mg per kg body weight per day) or higher than (100 or 250 mg per kg body weight per day) those seen in sham-operated mice (Fig. 2d) . This increase in bone mass affected vertebrae and long bones ( Fig. 2d and Supplementary Fig. 3g ) and was also present in nonovariectomized mice (Supplementary Fig. 4a ). There was no change in bone length or width in any of the groups treated with LP533401 ( Supplementary  Fig. 4b,c ). To rule out the possibility that LP533401, at the doses used in this study, exerts adverse effects on the gastroinstestinal tract or on hemostasis, we measured total gastrointestinal transit, colonic mobility and gastric emptying (three cardinal parameters of gastrointestinal homeostasis 8 ), as well as platelet numbers and coagulation time. l e t t e r S None of these gastrointestinal parameters were affected in LP533401-treated mice, even at 250 mg per kg body weight per day (Supplementary Fig. 4d-f) . Similarly, platelet numbers and coagulation times were similar in vehicle-and LP533401-treated mice (Supplementary Fig. 4g,h) . These results establish that LP533401 can rescue, through a bone anabolic mechanism, ovariectomyinduced osteoporosis in mice even when given at a low dose (25 mg per kg body weight per day) and late after ovariectomy and that it does so without deleterious consequences on hemostasis or intestinal motility. The rat is the rodent model of choice for postmenopausal osteoporosis because it replicates several key features of the estrogendeficient adult human skeleton, such as a bone loss accompanied by an increase in bone turnover rate and a specific estrogen-preventable cancellous osteopenia. Likewise, intermittent injections of parathyroid hormone (PTH) is the standard to which any new bone anabolic agent must be compared 9 . Hence, we ovariectomized rats at 12 weeks of age and left them untreated for 3 or 12 more weeks so that they developed a severe osteopenia ( Fig. 3 and Supplementary Fig. 5 ). We then treated sham-operated or ovariectomized rats for 4 weeks with either vehicle, a relatively high dose of PTH (80 µg per kg body weight per day, subcutaneously) 10 (Fig. 3a-c) or increasing amounts of LP533401 (25, 100 or 250 mg per kg body weight per day, orally) ( Fig. 3a-d) .
A histomorphometric analysis of vertebrae showed that LP533401 fully rescued the ovariectomy-induced osteopenia in rats ( Fig. 3a,d) , regardless of whether it was given 3 or 12 weeks after ovariectomy, and that it was efficacious even at the lowest dose used (25 mg per kg body weight per day) (Fig. 3d) . This rescue was due to an increase in osteoblast number and bone formation rate, whereas the osteoclast surface per bone surface was similar in untreated, PTH-treated ( Fig. 3a) and LP533401-treated ( Fig. 3a,d) ovariectomized rats. To determine whether LP533401 also affects bone mass in long bones that are load bearing, we used microcomputed tomography. Ovariectomy profoundly reduced bone volume, trabecular number and trabecular thickness and increased trabecular spacing in long bones (Fig. 3b,c) . LP533401, at all doses tested, increased trabecular number and trabecular thickness and reduced trabecular spacing in these bones, thereby increasing, in a dose-dependent manner, bone mass in ovariectomized rats when compared to vehicle-treated controls ( Fig. 3b-d) . Illustrating the sensitivity of the serotonergic regulation of bone formation, 25 mg per kg body weight per day of LP533401 rescued the ovariectomyinduced osteopenia in rats as it did in mice, although it caused only a 35-40% reduction in serum serotonin concentration (Figs. 2d and 3d and Supplementary Fig. 5h,i) . Although LP533401 seemed to be at least as efficient as the high-dose PTH regimen used in this experiment in vertebrae, this was not the case in long bones (Fig. 3a-c) . Ovariectomy also led to a decrease in cortical thickness, a key parameter of bone integrity 11 ; this decrease at the femur midshaft was rescued to equivalent degrees by PTH and LP533401 (250 mg per kg body weight per day) ( Fig. 4a) . We also analyzed two microarchitectural parameters, endocortical and periosteal circumference; both parameters were, as expected, larger after ovariectomy 12 ; LP533401 and PTH treatments decreased them to a similar extent (Supplementary Fig. 6) .
To measure bone quality, we subjected femur and vertebra samples from untreated, PTH-treated and LP533401-treated ovariectomized rats to a three-point bending test and a compression analysis to determine maximal load and stiffness, two surrogates l e t t e r S nature medicine VOLUME 16 | NUMBER 3 | MARCH 2010 3 1 1 of bone quality 13, 14 (Fig. 4b-e ). Both parameters were decreased after ovariectomy and restored to values seen in sham-operated rats by PTH and LP533401 (250 mg per kg body weight per day) treatments ( Fig. 4b-e ). Thus, daily oral administration of LP533401 can revert the bone loss and architectural deterioration caused by long-term gonadal failure in rats in a dose-dependent manner (Supplementary Fig. 5i) .
Given the progressive aging of the general population, post-menopausal osteoporosis is a growing public health concern. A major need in the treatment of this disease is to identify safe anabolic agents that can increase bone formation on a long-term basis and to such an extent that they compensate for the increase in bone resorption caused by menopause 1 . To date, only one treatment fulfills these criteria-intermittent injections of PTH 15, 16 . The fact that PTH is injectable and limited for use to a 2-year time period has been an incentive to search for new bone anabolic drugs 9 . We show here that an inhibitor of GDS synthesis acts as a bone anabolic agent that, when given to rodents for 4-6 weeks, can fully rescue gonadectomy-induced bone loss. That a high dose of PTH is more efficient than LP533401 in long bones but not in vertebrae raises the testable possibility that the two agents exert anabolic functions through different mechanisms.
Although the data presented here are promising, we remain fully aware that, as rodents have a lower rate of bone remodeling than l e t t e r S humans and lack Haversian remodeling, our results need to be confirmed in other species. Nevertheless, the fact that this small molecule can be administered orally, promotes only bone formation and, for the purpose of treating osteoporosis, is needed at a relatively small dose and only once daily, suggests that inhibitors of GDS synthesis have the potential to become a new class of bone anabolic drugs that can be added to the armamentarium to treat osteoporosis. This would be consistent with the fact that individuals with the high-bone-mass syndrome have low plasma serotonin concentrations 2, 17 .
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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